Company / Current Liabilities
Caribou Biosciences, Inc. Current Liabilities History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$25.4M
FY2025
5-year range
$25.4M / $30.7M
FY2021-FY2025
Trend
-17.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $28M to $25M over the past 2 years.
Based on SEC 10-K filings.
$25M in FY2025 with a 3-year CAGR of -3.3%.
Improved from $28M to $25M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -3.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -3.3%, indicating a declining trend.
- In FY2025, current liabilities decreased 17.1% year-over-year.
- Peak current liabilities was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.4M | -17.1% |
| FY2024 | $30.7M | +8.3% |
| FY2023 | $28.3M | +0.6% |
| FY2022 | $28.1M | +8.9% |
| FY2021 | $25.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026